Levulan (5-aminolevulinic acid) photodynamic therapy.    (DrugBank: Aminolevulinic acid, 5-Aminolevulinic acid)

1 disease
IDDisease name (Link within this page)Number of trials
34Neurofibromatosis1

34. Neurofibromatosis    [ 120 clinical trials,   182 drugs,   (DrugBank: 72 drugs),   84 drug target genes,   194 drug target pathways]
Searched query = "Neurofibromatosis", "NF1", "von Recklinghausen disease", "NF2"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 120 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01682811
(ClinicalTrials.gov)
November 20115/9/2012Phase I Photodynamic Therapy (PDT) for Benign Dermal Neurofibromas (NF1)Photodynamic Therapy for Benign Dermal Neurofibromas Using Levulan Kerastick For Topical Solution, Plus Illumination With Red LightNeurofibromatosesDrug: Levulan (5-aminolevulinic acid) uptake.;Drug: Levulan (5-aminolevulinic acid) photodynamic therapy.Harry T Whelan, MDNULLCompleted18 Years90 YearsAll10Phase 1United States